Gene-Specific Template (Updated 9-28-21): Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| Line 159: | Line 159: | ||
==References== | ==References== | ||
( | (''Instruction: Add PMIDs into the text above where references are appropriate - PMIDs will be used to insert references on the CCGA site and the reference list automatically generated'') | ||
<references /> | |||
(''Instruction: If a PMID is not available, such as for a book, please include the entire reference in this section'')<references /> | |||
===EXAMPLE Book=== | ===EXAMPLE Book=== | ||
| Line 166: | Line 167: | ||
===EXAMPLE Internet Resource=== | ===EXAMPLE Internet Resource=== | ||
Author name(s). Date (if possible). page title, website title, web address, and date accessed. | |||
#Cingam, S. R. and Koshy, N.V. (2017). Cancer, Leukemia, Promyelocytic, Acute (APL, APML). https://www.ncbi.nlm.nih.gov/books/NBK459352/ Accessed August 3, 2018. | #Cingam, S. R. and Koshy, N.V. (2017). Cancer, Leukemia, Promyelocytic, Acute (APL, APML). https://www.ncbi.nlm.nih.gov/books/NBK459352/ Accessed August 3, 2018. | ||
==Notes== | ==Notes== | ||
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. | <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. | ||